drugset / Trial / NCT03302650

Angiotensin II for Septic Shock Treatment

NCT03302650

Phase 3 Suspended 20 enrolled Cairo University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to investigate the effect of angiotensin II on microcirculation and peripheral perfusion in patients with septic shock.

Timeline

Start
2019-04-01
Primary completion
2019-08-01
Completion
2019-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiotensin II Peptide 20 ng
Background Norepinephrine Other / unclassified 0.7 ug/kg